Status:

COMPLETED

Study of the Transmission of Cytomegalovirus (CMV) Infection From Mother to Foetus

Lead Sponsor:

GlaxoSmithKline

Conditions:

Infections, Cytomegalovirus

Cytomegalovirus Infections

Eligibility:

FEMALE

18+ years

Phase:

NA

Brief Summary

This study is designed to evaluate maternal virological and immunological parameters to determine their ability to predict congenital cytomegalovirus (CMV) infection. When a pregnant woman is infected...

Eligibility Criteria

Inclusion

  • Subjects who the investigator believes that they can and will comply with the requirements of the protocol .
  • A pregnant female, 18 years of age or older at the time of study enrolment.
  • Women with confirmed primary CMV infection.
  • Written informed consent obtained from the subject.

Exclusion

  • Chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to study entry.
  • Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational pharmaceutical product.
  • Previous vaccination against CMV infection.
  • Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history or physical examination
  • Major congenital defects, serious chronic illness or organ transplantation.
  • Administration of immunoglobulins and/or any blood products within the three months preceding study enrolment or during the pregnancy.
  • Documented Human immunodeficiency virus (HIV)-positive subject.
  • Gestational age of more than 34 weeks, as determined by foetal ultrasound.

Key Trial Info

Start Date :

December 9 2010

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

June 17 2015

Estimated Enrollment :

160 Patients enrolled

Trial Details

Trial ID

NCT01251744

Start Date

December 9 2010

End Date

June 17 2015

Last Update

June 29 2020

Active Locations (9)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 3 (9 locations)

1

GSK Investigational Site

Brussels, Belgium, 1000

2

GSK Investigational Site

Brussels, Belgium, 1050

3

GSK Investigational Site

Brussels, Belgium, 1070

4

GSK Investigational Site

Charleroi, Belgium, 6000